Aerosol Pulmonary Immune EngineeringArticle Published on 2023-06-282024-09-05 Journal: Advanced drug delivery reviews [Category] update2024, [키워드] Asthma biologics Cancer COPD COVID-19 cystic fibrosis immune engineering Immunotherapy particulates pulmonary delivery Small molecules [DOI] 10.1016/j.addr.2023.114831 PMC 바로가기 [Article Type] Article
Inhalable neutralizing antibodies – promising approach to combating respiratory viral infectionsReview Published on 2023-02-012023-07-11 Journal: Trends in pharmacological sciences [Category] COVID19(2023년), [키워드] COVID-19 engineered antibody intranasal delivery monoclonal antibody pulmonary delivery SARS-CoV-2 [DOI] 10.1016/j.tips.2022.11.006 [Article Type] Review
Opportunistic etiological agents causing lung infections: emerging need to transform lung-targeted deliveryReview Article Published on 2022-12-262024-09-04 Journal: Heliyon [Category] 대상포진, [키워드] antimicrobial agents barrier Etiological agents Infection Inhalable drug lung pulmonary delivery [DOI] 10.1016/j.heliyon.2022.e12620 PMC 바로가기 [Article Type] Review Article
Gelatin Stabilizes Nebulized Proteins in Pulmonary Drug Delivery against COVID-19젤라틴은 COVID-19에 대한 폐 약물 전달에서 분무된 단백질을 안정화합니다Article Published on 2022-06-132022-09-11 Journal: ACS Biomaterials Science & Engineering [Category] Coronavirus, COVID19(2023년), SARS, 변종, [키워드] ACE2 acute respiratory syndrome acute respiratory syndrome coronavirus addition Aerogen airway angiotensin angiotensin-converting enzyme 2 biological molecule biological molecules can be used coordination coronavirus CoV-19 COVID-19 delivery distribution domain dosage drug effective ENhance enzyme experiment experiments feasibility fraction Fractions gelatin gelatin stabilization generate IFN-α2 infection with SARS-CoV-2 inhalation inhalation therapy inhibit interferon lung Lungs medication nebulization noninvasive pandemic Protein protocol pulmonary pulmonary delivery RBD-62 respiratory diseases SARS-CoV-2 significantly therapy transfer Vaccines variants [DOI] 10.1021/acsbiomaterials.2c00419 PMC 바로가기 [Article Type] Article
Inhibition of SARS-CoV-2 replication in the lung with siRNA/VIPER polyplexesArticle Published on 2022-05-012023-07-08 Journal: Journal of controlled release : official journal o [Category] COVID19(2023년), [키워드] Human precision-cut lung slices pulmonary delivery RNA therapeutics SARS-CoV-2 siRNA delivery [DOI] 10.1016/j.jconrel.2022.03.051 PMC 바로가기
Dual targeting powder formulation of antiviral agent for customizable nasal and lung deposition profile through single intranasal administrationArticle Published on 2022-03-282023-07-01 Journal: International journal of pharmaceutics [Category] COVID19(2023년), SARS, [키워드] ACE2, angiotensin-converting enzyme 2 antiviral agent COVID-19 COVID19, Coronavirus Disease 2019 Dry powder aerosol DSC, differential scanning calorimetry EF, Emitted fraction FPF, Fine particle fraction HPBCD, 2-hydroxypropyl-β -cyclodextrin intranasal delivery MERS-CoV, Middle East respiratory syndrome coronavirus NF, Nasal fraction NGI, Next Generation Impactor pulmonary delivery RF, Residual fraction SARS-COV-2, severe acute respiratory syndrome coronavirus-2 SD, Spray drying SEM, scanning electron microscopy SFD, Spray freeze drying Spray drying Spray freeze drying SREBP, sterol regulatory element binding protein TBA, Tert-Butyl alcohol TF, Throat fraction TFN, Two-fluid nozzle TGA, Thermogravimetric analysis USN, Ultrasonic nozzle [DOI] 10.1016/j.ijpharm.2022.121704 PMC 바로가기 [Article Type] Article
Nanotechnologies in Delivery of DNA and mRNA Vaccines to the Nasal and Pulmonary MucosaReview Published on 2022-01-112022-10-30 Journal: Nanomaterials [Category] COVID-19, [키워드] adjuvants Administered airway antigen-presenting cells caused clearance COVID-19 delivery DNA DNA vaccine enzyme epithelial exogenously facilitate Genetic Host ideal Immunity immunization in vitro induce infect Infection Infectious disease Inhaled intranasal delivery mRNA mRNA vaccine mucosa mucosal mucosal immune response mucosal surfaces Nanoparticles Nanotechnology nasal nucleic acid nucleic acid vaccine nucleic acid-based vaccine overcome pathogen physical PROTECT Protective protective immunity pulmonary pulmonary delivery recent SARS-CoV-2 transcribed vaccination Vaccine variety while [DOI] 10.3390/nano12020226 PMC 바로가기 [Article Type] Review
Mucoadhesive nanoformulations and their potential for combating COVID-19Commentary Published on 2021-11-032022-10-30 Journal: Nanomedicine [Category] COVID-19, MERS, SARS, [키워드] acute respiratory distress syndrome combating COVID-19 Cytokine storm human angiotensin-converting enzyme II mucoadhesive Mucus Hypersecretion Nasal Sprays pulmonary delivery Repurposed drug SARS-CoV-2 spike glycoprotein [DOI] 10.2217/nnm-2021-0287 PMC 바로가기 [Article Type] Commentary
Safety of inhaled ivermectin as a repurposed direct drug for treatment of COVID-19: A preclinical tolerance studyResearch article Published on 2021-10-012022-10-05 Journal: International immunopharmacology [Category] 신약개발, 치료법, 치료제, [키워드] Administered administration alterations Bioavailability Cell culture COVID-19 COVID-19 cases dose dose-dependent Gene Expression histopathological ICAM-1 IL-10 IL-13 IL-6 increase in Inhaled inhibited Ivermectin low dose lung male MCP-1 medication Mild objective outcome pre-clinical step profiles protein expression pulmonary pulmonary damage pulmonary delivery reduction in regimen Result Safety SARS-CoV-2 replication Serum level shown suggested therapeutic TNF-α Tolerance Toxicity treated Treatment was used were used X-ray diffraction [DOI] 10.1016/j.intimp.2021.108004 [Article Type] Research article
siRNA Therapeutics against Respiratory Viral Infections—What Have We Learned for Potential COVID‐19 Therapies?호흡기 바이러스 감염에 대한 siRNA 치료제 - 잠재적인 COVID-19 치료제에 대해 우리는 무엇을 배웠습니까?Review Published on 2021-01-272022-09-10 Journal: Advanced Healthcare Materials [Category] 치료제, [키워드] addition Antiviral antiviral drug antiviral drugs cause choice conserved COVID‐19 death develop Economy effective emerging respiratory virus evaluated FIVE global health Health highlighting host gene host genes host–viral interactions Infection infection sites Influenza inhalation inhibiting life Modification nanomedicine offer outbreak pandemic Potential Prevalence Prevent progress report prophylactically provide pulmonary pulmonary delivery Region regions Replication respiratory respiratory virus respiratory viruses resulting RNAi pathway SARS‐CoV‐1 SARS‐CoV‐2 SARS‐CoV‐2 sequence siRNA siRNAs swine flu target cell target cells target gene therapeutic use Therapeutics Treatment Vaccine Viral viral genome viral infection viral replication viral respiratory viruses [DOI] 10.1002/adhm.202001650 PMC 바로가기 [Article Type] Review